News
Participation in the EACME 2022 Conference
In September 2022 (from 15th to 17th) Tomasz Krawczyk, an associate of the Department of Philosophy and Bioethics participated in the EACME Conference 2022. The conference was organized by the European Association of Centres of Medical Ethics and took place at the Insubria University in Varese, Italy. During the conference he presented the poster entitled “Nothing […]
Participation in the 16th World Congress of Bioethics
From July 20 to 22, 2022 Department of Philosophy and Bioethics staff (REMEDY members) participated in the 16th World Congress of Bioethics. The congress took place in Basel, Switzerland. The host organization was Institute for Biomedical Ethics at University of Basel . During the three-day conference, the following presentations were given: Paola Buedo MD, MA: Ethics Lab: real-time […]
Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis
New article entitled Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis was published on 8th July 2022 in BMC Medicine.
How to counter misinformation using psychology
On 6 July 2022 at 10:00 am (Norwegian time) the #Webimmunization project team will organize an open midterm seminar. We have the pleasure to announce that the guest speaker will be Dr Jon Roozenbeek. Dr Roozenbeek is the British Academy Postdoctoral Fellow at the Cambridge Social Decision-Making Lab.
Lecture of Professor Jonathan Kimmelman
Ethical and Policy Issues with Individualized Clinical Trials
Recent years have witnessed growing interest and utilization of “individualized clinical trials”- that is, trials testing precision medicine therapies where patients are used as their own controls. In this talk I will describe the basic scientific principles behind individualized clinical trials. I will then explain various ethical and policy challenges in implementing individualized clinical trials, arguing that such studies maintain traditional tensions between research and care, and that individualized clinical trial methods, as currently implemented, present nontrivial validity threats and ethical challenges.
